



Impact of Dolutegravir-based Regimen on Tolerance and Virologic Suppression, Compared to Non-dolutegravir Regimen among PLHIV in Southern Senegal

Kalilou Diallo ^{a,b*}, Dame Mbengue ^{a,b}, Habibou Sarr ^{a,c},
Abdou Badiane ^d, Khadidiatou Diallo ^{a,b},
Mame Ngoné Coly ^{a,e}, Ludmillie Annie Badji ^f,
Bruce Shinga Wembulua ^g, Khardiata Diallo ^g,
Ansoumana Diatta ^{a,f} and Noel Magloire Manga ^{a,b}

^a Health Sciences Training and Research Unit, Assane Seck University of Ziguinchor, Senegal.

^b Department of Infectious Diseases, Peace Hospital in Ziguinchor, Senegal.

^c Microbiology Department of the Peace Hospital in Ziguinchor, Senegal.

^d Department of Nutrition, Cheikh Anta Diop University, Senegal.

^e Department of Hematology, Peace Hospital in Ziguinchor, Senegal.

^f Department of Pneumology, Peace Hospital in Ziguinchor, Senegal.

^g Department of Infectious Disease, Fann Hospital in Dakar, Senegal.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/AJRID/2024/v15i3336

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/114834>

Original Research Article

Received: 01/02/2024

Accepted: 04/04/2024

Published: 04/04/2024

*Corresponding author: E-mail: kalildiall@yahoo.fr;

ABSTRACT

Background: In 2020, Senegal began a transition to a Dolutegravir-based treatment as a first-line regimen in all new ART initiators in accordance with WHO recommendations.

Aims: To determine the virological suppression and the tolerance on patients under a dolutegravir-based regimen by comparison with patients on a regimen without dolutegravir after at least 6 months of treatment.

Materials and Methods: A cross-sectional study based on retrospective data (from January 2nd, 2017 to June 30th; 2022) involving 469 patients, 219 people were initiated with Dolutegravir regimen ART between Jan 2nd, 2020, and June 30th, 2022, and 250 patients treated using the old protocol (non-dolutegravir regimen). Patients who had received both the old protocol then switched to a DTG based regimen were excluded from the study.

A single questionnaire was used to collect data. Sociodemographic, clinical and virological parameters and the last control of the virological load were analyzed with Stata 16 software. Descriptive statistics and unvaried analysis were also carried-out.

Results: In the dolutegravir regimen ART group, 161 (73, 52%) of 219 were women and 58 (26.48) were men. The median participant age was 43.0 years (IQR 33.0–53.0) and the median time on ART was 28.0 months (23.0–36.0). The dolutegravir-based regimen combined tenofovir, lamivudine and dolutegravir. 15 (6, 85 %) were receiving tuberculosis treatment at the time of ART initiation. The proportion of patients screened at an advanced clinical stage of AIDS (WHO stage 3 or 4) were 63, 47%. People initiated on dolutegravir were more likely to be retained in care at 12 months (100% vs. 95.20%; $p=0.075$) and having viral suppression (96.80%vs. 96.40% ; $p=0.810$) compared with those initiated on non-dolutegravir-based regimens but the difference was not statistically significant. Fewer patients presented side effects due to triple therapy in the dolutegravir-based regimen group compared to the non-dolutegravir group (2.74% vs. 3.20%; $p=0.77$). In the dolutegravir based regimen the side effects were mainly vomiting, insomnia, and dizziness. The mean gain weight was $6,7 \pm 8,2$ kilograms.

For the non-dolutegravir regimen group, 195 (78.00%) were women. The median participants age was 43.0 years (IQR 34.0–53.0) and the median time on ART was 55.0 years (48.0–65.0) months. 18 (7, 20%) were receiving tuberculosis treatment at time of ART initiation. The therapeutic protocol combined TDF, lamivudine, Efavirenz in 225 cases (90%). A percentage of 59.20% patients were screened at an advanced clinical stage of AIDS (WHO Stage 3 and 4). In this group the side effects were mainly nausea and insomnia and the mean gain weight was $7,2 \pm 6,2$ kilograms.

Conclusion: The results of our study show a high rate of viral suppression, and good tolerance of the dolutegravir-based regimen in a decentralized setting.

Keywords: Doluteglavir; treatment; PLHIV; Senegal.

1. INTRODUCTION

HIV infection is a public health issue with an estimated 39 million persons living with HIV (PLHIV) worldwide, two-thirds of who reside in sub-Saharan Africa (SSA) [1].

Under WHO recommendations, a regimen based on efavirenz, a non-nucleotide reverse transcriptase inhibitors (NNRTI) was the preferred first-line treatment until 2018. Given the concerns about side effects, low genetic barrier and occurrence of drug resistance especially in low income settings as shown in several studies in Africa [2-3], where viral load and genotyping is not systematically realized, new recommendations have been made. For instance an alternative treatment based on dolutegravir,

an integrase strand transfer inhibitor (INTSI) has been recommended by the World Health Organization. This molecule has shown a better efficiency based on studies run in Europe then in Africa [4-5] due to the improvement of the tolerance, reduction of treatment discontinuations with fewer cases of resistance.

Senegal is one of the first countries in sub-Saharan Africa to set up an access program to ART in 1998. It is also one of the first countries in Africa to have decided to make ART free in 2003 [6]. In 2020, Senegal began a transition to Dolutegravir-based treatment regimens in accordance with WHO recommendations. This regimen was first initiated in newly infected patients then gradually in patients under other protocols. After three years of switching to

dolutegravir, we conducted this study with the aim of comparing the tolerance and effectiveness of these new protocols to those pre-existing regimens, especially based on NNRTI in a decentralized environment.

2. METHODOLOGY

2.1 Study Design and Participants

The study took place in the HIV outpatient treatment unit at Kolda's health center (UTA) on patients enrolled from January 2nd, 2017 to December 31st, 2022.

It is a cross-sectional and descriptive study on two groups of subjects: patients treated using the old protocol without DTG (from January 2nd, 2017 to December 31st, 2020) and patients treated with new protocol including DTG (from January 2nd, 2020 to June 30th, 2022) followed in the infectious diseases department of Kolda's hospital.

The old protocol associated two nucleoside reverse transcriptase inhibitors (NRTI) and one non-nucleoside reverse transcriptase inhibitors (NNRTI) or two NRTI and one Protease inhibitors (PI). The new protocol associates two NRTI and one INTSI (DTG).

The duration of exposure to dolutegravir had to be at least 6 months. Each patient included had to have a monitoring of the viral load available after at least 6 months of ART. We excluded pretreated PLHIV with the old protocol who had switched to dolutegravir from the comparison group. Patients whose files were unusable due to lack of information were not included.

2.2 Data Collection

Data was collected on a survey sheet. A questionnaire was developed to collect data on socio-demographic (age, sex, level of education, HIV status disclosure) clinical (duration of HIV infection, clinical stage at discovery of HIV, weight, presence of opportunistic infection), therapeutic (ART protocol, side effects), virological (viral load, virological failure, virological success) evolution (body mass index) parameters. The questionnaire was filled out using patients' medical records, patients' interrogation and the UTA's data base.

The viral load was considered undetectable when it was less than 50 copies per milliliter of

blood. Viral success was a viral load below 1000 copies per milliliter of blood.

2.3 Statistical Analysis

Data were computed using Excel 97- 2003 and analysed using Stata/Special 16 software (Stata Corporation, Texas, and USA). Results were expressed as mean \pm standard deviation for continuous variables and proportion for categorical variables. Student t-test was used for mean comparisons and Pearson's chi-square test for categorical variables comparison. P values < 0.05 were considered significant for all analysis.

3. RESULTS

A total of 469 PLHIV were included in this study, with 219 who initiated treatment with a dolutegravir-based regimen and 250 with a non-dolutegravir regimen. The patients' average age did not differ significantly between the two groups (41.63 \pm 12.89 versus 39.56 \pm 12.98, P=0.085) respectively. We also noted in both groups a female predominance (73.52% versus 78.00%, p= 0.257), a significant proportion of married people (77.31% versus 72.29%, p= 0.214), and patients who haven't shared their HIV status with their partners (27.06% versus 34.60%, P= 0.083). The majority of patients were illiterate (50.68% versus 57.20%, P = 0.158). (Table 1).

The proportions of comorbidities found: the proportion of diabetes did not differ in the two groups (7.76% versus 8.00%, p = 0.924), however hypertension was significantly higher among patients on ART based on dolutegravir compared to patients on the non-dolutegravir group (21.00% versus 11.60%; P: 0.006). Tuberculosis was the revealing condition in 15 (6, 85%) cases in the dolutegravir based regimen group and 18 (7, 20%) cases in the other group (Table 2).

The proportions of patients presenting weight loss (BMI < 18.5 kg/m²) at inclusion did not differ significantly between the two groups (47.03% versus 43.20%, P = 0.405). HIV-HBV co-infection was similar in both groups (5.48% versus 5.60 %, P= 0.545). The proportions of patients screened at an advanced clinical stage of AIDS (WHO stage 3 or 4) were significant in both groups (63.47% versus 59.20%, P= 0.344). According to the serological profile, HIV type-1 is predominant with 88.91% (n = 469). The mean duration on ART was significantly higher in

patients pretreated with therapeutic regimens not including dolutegravir (28.95 ± 7.80) versus 55.67 ± 11.93) ($P < 0.0001$) (Table 2). The dolutegravir-based regimen combined tenofovir, lamivudine and dolutegravir while the majority (90%) of pretreated patients were on an ART regimen combining TDF, lamivudine, Efavirenz as first line treatment (Table 2). Fewer patients experienced side effects related to triple therapy in the dolutegravir-based regimen group compared to the non-dolutegravir group (2.74% vs 3.20%; $p=0.77$) (Table 3). In the dolutegravir based regimen the side effects were mainly vomiting (0,91%), insomnia (0,91%), and dizziness (0,46%) while in the non-dolutegravir group the side effects were mainly nausea(0,80%) and insomnia (0,80%).

The undetectable viral load rate was slightly higher in the dolutegravir-based regimen group compared to the non-dolutegravir regimen group, but the difference was not statistically significant (97.72% vs 97.60%; $p = 0.933$) (Table 1). In the dolutegravir-based regimen, viral success was higher in females and patients aged less than 35-year-old (Table 4). As for the non-dolutegravir group, the viral success was higher in males and patients aged less than 35 (Table 5). The viral suppression in PLHIV under tuberculosis treatment was higher in the dolutegravir group compared to the non-dolutegravir group (100% versus 94,44%) (Table 4). Viral failure (Viral load >1000 copies/ml) was less frequent in the dolutegravir group than in the group without

Table 1. Socio-demographic characteristics of Respondents

Characteristics	Dolutegravir-based regimen (N=219)	Non-dolutegravir regimen (N=250)	P-value
Gender			
Female	161 (73.52%)	195 (78.00%)	0,257
Male	58 (26.48%)	55 (22.00%)	
Age (years)			
< 35	59 (26.94%)	72 (28.80%)	
35 – 49	91 (41.55%)	85 (34.00%)	
>50	69 (31.51%)	93 (37.20%)	
Median (IQR)	43 (IQR 33.0–53.0)	42 (IQR 34.0–53.0)	
Level of education			
Illiterate	111 (50.68 %)	144 (57.60%)	
Primary	82 (37.44%)	74 (29.60%)	
Secondary	21 (9.59%)	32 (12.80%)	
University	5 (2.28 %)	0 (0.00%)	
HIV status disclosure			
Yes	159 (72.94%)	155 (65.40 %)	0.083
No	59 (27.06%)	82 (34.60%)	
Viral success < 50 copies/ml	212 (96.80%)	241 (96.40%)	0.810
Viral failure > 1000 copies/ml	1 (0.46%)	3 (1.20%)	
ART regimen			
TDF+3TC+DTG	219 (100%)	0	
TDF+3TC+EFV	0 (0.00%)	225 (90%)	
TDF+3TC+LPv	0 (0.00%)	12 (4,80%)	
AZT+3TC+LPv	0 (0.00%)	8 (3,20%)	
AZT+3TC+NVP	0 (0.00%)	4 (1,60%)	
ABC+3TC+EFV	0 (0.00%)	1 (0,40%)	
Patients after 12 months			
Regularly followed	219 (100 %)	238 (95.20%)	0.075
Lost of sight	0 (0,00%)	12 (4.80%)	
Mean BMI after at least 12 months of ART treatment	22.19 \pm 4.4	22.42 \pm 4.5	0.581
Mean weight gain after 12months of treatment	6,7 \pm 8,2	7,2 \pm 6,2	0,503

Table 2. Clinical characteristics of respondents

	Dolutegravir-based regimen (N=219)	Non-dolutegravir regimen (N=250)	
WHO Stage at enrolment			0,344
no. (%)			
1	41 (18, 72)	45 (18, 00)	
2	39 (17, 81)	57 (22, 80)	
3	118 (53, 88)	125 (50, 00)	
4	21 (9, 59)	23 (9, 20)	
Co-morbidity			
Hypertension no. (%)	46 (21.00)	29 (11.60)	0.006
Diabetes no. (%)	17 (7.76)	20 (8.00)	0.924
HIV-HBV Co-infection no. (%)	12 (5, 48)	14 (5, 60)	
Tuberculosis at ART initiation no. (%)			
Known tuberculosis	15 (6, 85)	18 (7, 20)	0.882
No tuberculosis	204 (93.15)	232 (92.80)	
HIV profile no. (%)			
Type 1	194 (88.58)	223 (89.20)	0.576
Type 2	18 (08.21)	17 (06.8)	
Type 1+2	7 (03.17)	10 (04.00)	
BMI at admission no. (%)			
Mean	22.19 ±4.4	22.42 ± 4.5	
< 18,5	103 (47.03)	108 (43.20)	0.443
18,5- 24,9	87 (39.73)	114 (45.60)	
25 – 29,9	23 (10.50)	24 (9.60)	
30 – 34,9	6 (2.74)	3 (1.20)	
35 – 39,9	0 (0.00)	1 (0.40)	
Mean ART duration	28.95± 7.8	55.67± 11.93	0.0000
Viral success < 50 copies/ml	212 (96.80)	241 (96.40)	0.810
Viral failure > 1000 copies/ml	1 (0.46)	3 (1.20)	
ART regimen			
TDF+3TC+DTG	219 (100)	0	
TDF+3TC+EFV	0 (0.00)	225 (90)	
TDF+3TC+LPv	0 (0.00)	12 (4,80)	
AZT+3TC+LPv	0 (0.00)	8 (3,20)	
AZT+3TC+NVP	0 (0.00)	4 (1,60)	
ABC+3TC+EFV	0 (0.00)	1 (0,40)	
Patients after 12months			
Regularly followed	172 (78.54%)	245 (98.00)	

Table 3. Repartition of side effects in both groups during their last 6 months of treatment

Type of side effects	Dolutegravir-based regimen (N=219)	Non-dolutegravir regimen (N=250)
Dizziness no. (%)	1 (0,46)	1 (0.40)
Acute diarrhea no. (%)	1 (0,46)	1 (0.40)
Vomiting no. (%)	2 (0,91)	0 (0.00)
Nausea no. (%)	0 (0.00)	2 (0.80)
Headache no. (%)	0 (0.00)	1 (0.40)
Insomnia no. (%)	2 (0,91)	2 (0.80)
Skin rash no. (%)	0 (0.00)	1 (0.40)
Total	6 (2.74)	8 (3.20)

Table 4. Subgroup Analysis of Proportion of Participants under dolutegravir-based regimen with a Viral Load of Less Than 50 Copies per Milliliter after at least 6 months of treatment

Dolutegravir-based regimen (N=2019)	Viral success < 50 copies/ml (%)	p-value
Gender		0.318
Female	157 (97, 52)	
Male	55 (94, 83)	
Age (years)		0.985
< 35	57 (96.61)	
35 – 49	88 (96.70)	
> 50	67 (97.10)	
Tuberculosis at ART initiation		0.644
Known tuberculosis	15 (100)	
No tuberculosis	107 (96.57)	

Table 5. Subgroup analysis of proportion of participants under a non-dolutegravir based regimen with a viral load of less than 50 copies per milliliter after at least 6 months of treatment

Non-dolutegravir regimen	Viral success < 50 copies/ml	p-value
Gender		0.318
Female	187 (95, 90)	
Male	54 (98, 18)	
Age (years)		0.872
< 35	70 (97.22)	
35 – 49	82 (96.47)	
>50	89 (95.70)	
Tuberculosis at ART initiation		
Known tuberculosis	17 (94.44)	
No tuberculosis	224 (96.55)	

dolutegravir (1 versus 3) (Table 1). Mean body mass index at ART initiation did not differ in the two groups. The weight gain was lower in the dolutegravir based regimen group but the difference was not statistically significant $6,7 \pm 8,2$ kg versus $7,2 \pm 6,2$ kg. The occurrence of obesity was not significantly different in the two groups [23.74%] versus [23.20%], $P = 0.89$). (Table 1).

4. DISCUSSION

In this study, we compared data on viral suppression and tolerability of dolutegravir based regimens of 219 treatment-naive patients with those of 250 patients pretreated with a non-dolutegravir regimen for HIV-1 and HIV-2 in decentralized and resource-limited settings.

We observed in both groups a female predominance (75.9%). These results are in agreement with data from the CNLS (National council for the fight against AIDS) 2021 in Senegal [12]. This female predominance has also been found in several studies in Africa:

[7,8,9,10,11,13]. However, a meta-analysis of 13 cohorts by Egger [14] bringing together European and North American countries suggested a male predominance. This difference between the countries of the North and the South finds two explanations: on one hand, the predominance of heterosexual transmission in the South associated with female vulnerability; on the other hand the relatively high role of homosexuality and injection drug use in the North in the transmission of the disease.

The median age in both groups was 42.0 years (IQR 33.0–53.0). This result was similar to the ones found in multiple studies in Africa [7,8,9,10,11]. Indeed, HIV infection mostly affects the sexually active age group corresponding to the population of young adults due to their exposure to certain risk factors, especially economic insecurity and the relaxation of social control, notably in urban areas.

Majority of HIV infection in both groups were detected at an advanced clinical stage of AIDS

(WHO stage 3 or 4) (63.47% versus 59.20%, $P = 0.344$). However, this result is less than the ones found in studies run in Senegal in 2009 and 2011 [10,11]. That difference can be explained by the strategy 95-95-95 launched by UNAIDS in 2014 with the aim of ending AIDS pandemic by 2030. HIV diagnosis is the crucial first step of that strategy [15]. The advanced clinical stage is a vulnerability factor for patients both to the disease itself and the opportunistic conditions. It illustrates a diagnostic delay which remains frequent in our developing countries; the reasons for this delay can be explained by poverty, lack of information, the attitude of hiding the disease because of the risk of stigmatization and discrimination from the populations, the geographical and especially financial inaccessibility to healthcare structures [10]. This despite the freeness and efforts made to decentralize the screening in Senegal.

The proportion of weight loss at inclusion was significant and did not differ significantly between the two groups (47.03% versus 43.20%, $P = 0.405$). Studies have revealed that in the very advanced stages of AIDS there is a reduction in nutritional intake, an increase in energy expenditure linked to basal metabolism due to viral replication [16,17,18]. This viral presence triggers proteolysis which leads to muscle damage, thus causing an imbalance in the nitrogen balance and an exaggerated loss of lean tissue [16].

According to the serological profile, HIV type-1 is predominant with 88.91% ($n = 469$). This high prevalence of HIV-1 is explained by its greater virulence, which is characterized by greater transmissibility both sexually and from mother to child. This is how HIV-1 constitutes the serotype solely responsible for the current pandemic [19].

Senegalese guidelines recommend a double dose of dolutegravir in first line for patients under tuberculosis treatment. The viral suppression in PLHIV under tuberculosis treatment was higher in the dolutegravir group compared to the non-dolutegravir group. This result is in accordance to the clinical trial INSPIRING that showed a good tolerance and an acceptable viral suppression [20].

Senegal guidelines recommend than dolutegravir for people initiating ART who are receiving the standard rifampicin-containing tuberculosis treatment. However, we found that over half of those receiving tuberculosis treatment in our

study did receive dolutegravir and, among this group, the beneficial effect of dolutegravir on viral suppression was even stronger compared with those without tuberculosis.

After monitoring patients on ART for at least six months, we observed a progressive increase in weight gain in both groups. This increase was slightly greater in the group without dolutegravir with a mean weight gain of 7.2 ± 6.2 and a BMI of 22.42 ± 4.5 kg/m² compared to a mean weight gain of 6.7 ± 8.2 kg and BMI 22.19 ± 4.4 in the dolutegravir group but the difference was not statistically significant ($p: 0.58$). This variation in weight gain in the two groups could be due to the fact that the average duration of ART treatment is longer in the group without dolutegravir (55.67 ± 11.93 versus 28.95 ± 7.80 ; ($P < 0.0001$). The usage of anthropometrics parameters including BMI as a marker of the effectiveness of ART has been described and remains important in settings with limited resources [21,22,23, 24]. This weight gain in our study is close to the one found in patients followed in South Africa [23,25]. However, several studies have found the occurrence of significant weight gain under ART based on dolutegravir in Bouaké [26,26,25,27]. Dolutegravir would therefore play a role in patients weight gain. According to the literature, various mechanisms explain weight gain in PLHIV. Weight gain has recently appeared as a main side effect of antiretroviral treatment, potentially increasing the associated cardiovascular risks and having a negative impact on the quality of life of people living with HIV. This weight gain undoubtedly has a multifactorial origin and is of variable magnitude depending on the anti-integrase, the associated ARVs, the sex, the previous weight, the CD4 nadir and ethnic origin. We studied, in patients switching from triple therapy based on dolutegravir (DTG) to dual therapy, the evolution of weight gain [28]. Indeed, HIV infection and ART itself would lead to intestinal lesions causing an increase in fungal translocation and therefore an increase in the Beta D glucan (BDG) marker. A higher BDG would be associated with greater fat gains under antiretroviral treatment [29].

Retention for 12 months was significant among patients newly initiated to ART including dolutegravir in our cohort. This finding was observed in a therapeutic trial where people initiated to dolutegravir were more likely to be retained in care for 12 months (adjusted RR 1.09, 95% CI 1.04 to 1.14; adjusted risk

difference 5.2%, 2.2 to 8.4). This high rate of retention of patients on dolutegravir-based ART could be explained by increased tolerance [30,31,32]. Indeed, in our study, fewer patients experienced side effects linked to triple therapy in the dolutegravir-based regimen group compared to the group without dolutegravir (2.74% vs 3.20%; $p=0.77$).

The viral success rate (measured by the proportion of participants with a viral load <50 copies per milliliter after at least 6 months on ART) was slightly higher in the dolutegravir-based regimen group, compared to the non-dolutegravir regimen group however there was not a statistically significant difference (97.72% vs 97.60%; $p=0.933$). This viral success rate observed in our study was higher compared to those found in several others: 88% in the group having received dolutegravir, abacavir and lamivudine in the SINGLE2 trial [33] and 90% in the group that received dolutegravir and two NRTIs in the FLAMINGO trial [34]. Studies have shown viral suppression was impaired in participants with a high baseline viral load. However, in our study, the baseline viral load was not measured in our patients before starting ART. This could explain the difference in viral success rates. Furthermore, an improvement in viral suppression over 12 months with dolutegravir was observed in treatment-naïve patients in two clinical trials in Africa. [30,35]. Public health data from Brazil showed good safety outcomes [36] and better viral suppression over 12 months in people initiated on dolutegravir compared to those on efavirenz [37], but the proportion on dolutegravir was low and there was no assessment of retention in care.

In our study we did not look for resistance to ARVs, particularly to dolutegravir. Studies from Malawi, Lesotho, and Uganda suggest low levels of HIV resistance mutations to dolutegravir and high levels of viral suppression in people who transitioned to dolutegravir, but did not compare results with those of people remaining on dolutegravir-free regimens [37,38,39]. A retrospective cohort study of 3,108 people from four African countries have found that people who transitioned to dolutegravir had better viral suppression than those who remained on the same first- or second-line treatment [40]. Dolutegravir-based regimens are associated with a reduced need to switch to other antiretrovirals and there is a lower risk of developing major antiretroviral resistance mutations compared to efavirenz-based regimens [41,42].

5. CONCLUSION

This study showed that patients on treatment based on dolutegravir have a high rate of virological success, a low rate of viral failure and good tolerance similar or better than other regimens mainly with efavirenz. Other regimens even though the improvements in terms of retention in care and viral suppression are modest, constitutes an asset for achieving the 95-95-95 objectives in our context.

CONSENT AND ETHICAL APPROVAL

Prior to participation, participants were informed about the study's objectives and procedures, and their written consent was obtained. Both the regional health direction and the UTA's director gave their authorization. Each survey sheet was assigned an anonymous number.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. UNAIDS. Report on global HIV/AIDS epidemic; 2023.
2. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. *Lancet Infect. Dis.* 2018;18:346–355. DOI: 10.1016/S1473-3099(17)30702-8, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
3. World Health Organization (2019). HIV DRUG RESISTANCE REPORT 2019. Geneva, Switzerland. Available: <https://apps.who.int/iris/rest/bitstreams/1238263/retrieve> (Accessed April 21, 2022). [Ref list]2&3 implé
4. Dorward J, Lessells R, Drain PK, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. *Lancet HIV.* 2018;5:e400–04

5. Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. *EClinicalMedicine*. 2020;28:100573
6. Alice Desclaux Isabelle Lanièce Ibra Ndoye Bernard Taverne. L'Initiative sénégalaise d'accès aux médicaments antirétroviraux : Analyses économiques, sociales, comportementales et médicales. ANRS - Collection sciences sociales et sida, Paris; 2002.
7. Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, Lewis L, Bottomley C, Maraj M, Lessells RJ, Naidoo K, Butler CC, Van Heerden R, Garrett N. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study. *Lancet HIV*. 2023;10(5):e284-e294
8. Koy T, Mukumbi H, Muteba GL, Donnen P, Wilmet-Dramaix M. Profil comparatif et évolutif des personnes infectées par le virus de l'immunodéficience humaine traitées aux antirétroviraux à Kinshasa, République Démocratique du Congo. *Pan African Medical Journal*. 2014 ;19.
9. Matthew P, Fox M and Rosen S. Patient retention in antiretroviral therapy Programs up to three years on treatment in sub-Saharan Africa: 2007-2009, systematic review. *Tropical medicine and International Health*. 2010;15 (s1):1-15
10. Manga NM, Diop SA, Ndour CT, Dia NM, Mendy A, Coudec M, et al. [Late diagnosis of HIV infection in the Fann, Dakar clinic of infectious diseases: Testing circumstances, therapeutic course of patients, and determining factors]. *Med Mal Infect*. 2009;39:95-100
11. Fortes Déguénonvo L, Manga NM, Diop SA, Dia Badiane NM, Seydi M, Ndour CT, et al. Profil actuel des patients infectés par le VIH hospitalisés à Dakar (Sénégal). *Bull Société Pathol Exot*. 2011;104(5):366-70
12. CNLS. Rapport annuel; 2021. Available: <https://www.cnls-senegal.org/wp-content/uploads/2022/06/Rapport-CNLS-2021-1.pdf>
13. Chas J, Hema A, Slama L, Kabore F, Lescure FX, Fontaine C, et al. The Day Hospital of the University Hospital, Bobo Dioulasso: An Example of Optimized HIV Management in Southern Burkina Faso. *PloS one*. 2015;10: e0125588
14. Egger M, Sterne J, Phillips A. Prognostic importance of initial response in HIV1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. *Lancet*. 2003;362:679-86.
15. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90. An ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2014.
16. Macallan DC, Margaret A, Nurlan MC, Milne E, Graham CA, Garlick PJ. Whole-body protein turnover from leucine kinetics and the response to nutrition in human immune deficiency virus infection. *Am J Clin Nutr*. 1995;61(4):818-826. [PubMed] [Google Scholar]
17. Yarasheski X, Kevin E, Jeffrey J, Zachwieja, Jennifer Gischler, Jan Crowley, Mary M Horgan, William G Powderly. Increased plasma Gln and Leu rate and inappropriately low muscle protein synthesis rate in AIDS wasting. *J. Physiol*. 1998;275(38):E577-83. [Article PMC gratuit] [PubMed] [Google Scholar]
18. Mulligan KVV, Tai, Schamberlan M. Energy expenditure in Human Immunodeficiency virus infection. *N Engl J Med*. 1997;336:70-71. [PubMed] [Google Scholar]
19. OMS. Rapport VIH; 2022.
20. Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients coinfecting with tuberculosis and human immunodeficiency virus: A multicenter, noncomparative, open-label, randomized trial. *Clin Infect Dis* 2020;70: 549-56
21. World Health Organization. Working Document on Monitoring and Evaluating of National ART Program in the Rapid Scale upto 3. Disponible et consulté le 25 Août; 2013.
22. Messou E, Gabillard D, Moh R, Inwoley A, Sorho S, Eholié S, Rouet F, Seyler C, Danela C, Anglaret X. Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults. *Bulletin of*

- theWorld Health Organization. June 2008,86(6):435-442.
23. Hurley E, Coutsooudis A, Giddy J, Knight S E, Loots E, Esterhuizen T M. Weight evolution and perceptions of adults living with HIV following initiation of antiretroviral therapy in a South African urban setting. *SAMJ*. 2011;101(9):645-650.
 24. Kadiané-Oussou NJ, Koné D, Aba YT, Yapo MT, Karidioula JM, Tiéoule SC, Kra O. Devenir à douze mois des patients infectés par le virus de l'immunodéficience 1 initiant le dolutégravir à Bouaké (Côte D'Ivoire) de 2020 à 2021. *Rev Mali Infect Microbiol*. 2023 ;18(2).
 25. Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV1 infection (ADVANCE): Week 96 results from a randomized, phase 3, non-inferiority trial. *Lancet HIV* 2020;7:e666 76
 26. Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. *J Acquir Immune Defic Syndr*. 2017;76:527-31.
 27. Masson E. EM-Consulte. [cited August 22, 2023]. Weight gain induced by dolutegravir in Cameroon: 96-week follow-up of the ANRS 12313 - NAMSAL trial. Available: <https://www.emconsulte.com/article/1383214/prise-de-poids-induite-par-le-dolutegravir-au-came>
 28. M.-A. Khuong-Josses, B. Frison, Q. Bougault, M. Poupard, N. Sayre, A. Boussairi. Does switching to dual therapy (dolutegravir + lamivudine) have an influence on the weight of patients on dolutegravir-based triple therapy? 21st National Infectiology Days / Medicine and infectious diseases. 2020;50:S31–S199
 29. Dirajlal-Fargo S, Moser C, Rodriguez K, El Kamari V, Funderburg N, Bowman E, et al. Changes in the fungal marker β -D-glucan after antiretroviral therapy and association with adiposity. *Open Forum Infectious Diseases*. 2019;6.
 30. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. *N Engl J Med*. 2019;381:803–15.
 31. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med*. 2013;369:1807.
 32. Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. *N Engl J Med*. 2019; 381:816–26. singl
 33. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. *N Engl J Med*. 2013;369:1807-18.
 34. Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomized, open-label, phase 3b study. *Lancet HIV*. 2015;2(4):e127-e136.
 35. Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, Lewis L, Bottomley C, Maraj M, Lessells RJ, Naidoo K, Butler CC, Van Heerden R, Garrett N. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study. *Lancet HIV*. 2023;10 (5):e284-e294.
 36. Batista CJB, Correa RG, Evangelista LR, et al. The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. *Medicine (Baltimore)*. 2019;98:e14828.
 37. Meireles MV, Pascom ARP, Duarte EC, McFarland W. Comparative effectiveness of first-line antiretroviral therapy: Results from a large real-world cohort after the implementation of dolutegravir. *AIDS*. 2019;33:1663–68.
 38. Schramm B, Temfack E, Descamps D, et al. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transition to dolutegravir first-line therapy in Malawi: a prospective cohort study. *Lancet HIV*. 2022;9:e544–53.
 39. Nabitaka VM, Nawaggi P, Campbell J, et al. High acceptability and viral suppression of patients on dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study. *PLoS One*. 2020;15:e0232419.

40. Esber A, Dear N, Shah N, et al. Virologic impact of the dolutegravir transition: prospective results from the multinational African Cohort Study. *J Acquir Immune Defic Syndr.* 2022;91:285–89.
41. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med.* 2013;369:1807–18.
42. Wainberg MA, Han YS. Will drug resistance against dolutegravir in initial therapy ever occur? *Front Pharmacol.* 2015;6:90.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/114834>